A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Study Summary

The purpose of the study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy of teclistamab at RP2D for Japanese participants in Phase 2 part.

Conditions

Hematologic Malignancies

Interventions / Drugs

Teclistamab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment40 participants

Primary Completion—

Lead SponsorJanssen Pharmaceutical K.K.

Data Retrieved2026-04-11 02:55:31.549800+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.